Milestone Pharmaceuticals Inc. (MIST) stock
MISTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.52−0.14 (-20.63%)
Close on Nov 13, 2026Market cap $64.74MP/E –Yield –
Milestone Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Milestone Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $15.74M, down 4.8% year over year. For fiscal 2025 it was $18.11M, up 26.1% from the year before. The highest annual figure on record is $41.99M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.11M | +26.1% |
| FY2024 | Dec 31, 2024 | $14.36M | -53.8% |
| FY2023 | Dec 31, 2023 | $31.05M | -22.0% |
| FY2022 | Dec 31, 2022 | $39.83M | +3.0% |
| FY2021 | Dec 31, 2021 | $38.67M | +12.1% |
| FY2020 | Dec 31, 2020 | $34.49M | -17.9% |
| FY2019 | Dec 31, 2019 | $41.99M | +149.2% |
| FY2018 | Dec 31, 2018 | $16.85M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.46M | -12.2% |
| Q2 FY2026 | Jun 30, 2026 | $3.51M | -4.4% |
| Q1 FY2026 | Mar 31, 2026 | $3.25M | -34.7% |
| Q4 FY2025 | Dec 31, 2025 | $5.52M | +40.1% |
| Q3 FY2025 | Sep 30, 2025 | $3.94M | -0.6% |
| Q2 FY2025 | Jun 30, 2025 | $3.67M | +30.3% |
| Q1 FY2025 | Mar 31, 2025 | $4.98M | +36.8% |
| Q4 FY2024 | Dec 31, 2024 | $3.94M | -27.7% |
| Q3 FY2024 | Sep 30, 2024 | $3.96M | -41.0% |
| Q2 FY2024 | Jun 30, 2024 | $2.82M | -67.4% |
| Q1 FY2024 | Mar 31, 2024 | $3.64M | -64.5% |
| Q4 FY2023 | Dec 31, 2023 | $5.45M | -48.5% |
| Q3 FY2023 | Sep 30, 2023 | $6.72M | -31.6% |
| Q2 FY2023 | Jun 30, 2023 | $8.62M | -19.1% |
| Q1 FY2023 | Mar 31, 2023 | $10.26M | +17.0% |
| Q4 FY2022 | Dec 31, 2022 | $10.58M | -3.1% |
| Q3 FY2022 | Sep 30, 2022 | $9.83M | +1.0% |
| Q2 FY2022 | Jun 30, 2022 | $10.66M | +13.0% |
| Q1 FY2022 | Mar 31, 2022 | $8.77M | +2.0% |
| Q4 FY2021 | Dec 31, 2021 | $10.92M | +89.3% |
| Q3 FY2021 | Sep 30, 2021 | $9.73M | +18.3% |
| Q2 FY2021 | Jun 30, 2021 | $9.43M | +9.3% |
| Q1 FY2021 | Mar 31, 2021 | $8.60M | -27.6% |
| Q4 FY2020 | Dec 31, 2020 | $5.77M | -59.2% |
| Q3 FY2020 | Sep 30, 2020 | $8.23M | -13.8% |
| Q2 FY2020 | Jun 30, 2020 | $8.62M | -18.1% |
| Q1 FY2020 | Mar 31, 2020 | $11.87M | +52.9% |
| Q4 FY2019 | Dec 31, 2019 | $14.15M | +93.9% |
| Q3 FY2019 | Sep 30, 2019 | $9.55M | +144.1% |
| Q2 FY2019 | Jun 30, 2019 | $10.53M | +312.7% |
| Q1 FY2019 | Mar 31, 2019 | $7.77M | +151.2% |
| Q4 FY2018 | Dec 31, 2018 | $7.30M | – |
| Q3 FY2018 | Sep 30, 2018 | $3.91M | – |
| Q2 FY2018 | Jun 30, 2018 | $2.55M | – |
| Q1 FY2018 | Mar 31, 2018 | $3.09M | – |
See a number that looks wrong?